Versant Venture Management LLC decreased its position in shares of Glaukos Corp. (NYSE:GKOS) by 17.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 2,586,985 shares of the company’s stock after selling 549,247 shares during the period. Glaukos Corp. makes up approximately 76.5% of Versant Venture Management LLC’s portfolio, making the stock its largest position. Versant Venture Management LLC owned approximately 7.96% of Glaukos Corp. worth $75,436,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Spark Investment Management LLC purchased a new position in shares of Glaukos Corp. during the first quarter worth approximately $300,000. Strs Ohio boosted its position in shares of Glaukos Corp. by 409.1% in the second quarter. Strs Ohio now owns 11,200 shares of the company’s stock worth $326,000 after buying an additional 9,000 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in shares of Glaukos Corp. during the second quarter worth approximately $614,000. Geode Capital Management LLC boosted its position in shares of Glaukos Corp. by 1.0% in the first quarter. Geode Capital Management LLC now owns 41,932 shares of the company’s stock worth $706,000 after buying an additional 405 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in shares of Glaukos Corp. during the first quarter worth approximately $1,235,000. 71.91% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Glaukos Corp. (NYSE:GKOS)

Glaukos Corp. (NYSE:GKOS) traded down 0.31% during mid-day trading on Friday, hitting $35.62. The company’s stock had a trading volume of 171,257 shares. The stock’s market cap is $1.18 billion. Glaukos Corp. has a 52-week low of $14.25 and a 52-week high of $39.82. The company’s 50 day moving average is $35.23 and its 200-day moving average is $28.39.

Glaukos Corp. (NYSE:GKOS) last announced its quarterly earnings data on Monday, August 1st. The company reported $0.06 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.10. Glaukos Corp. had a negative return on equity of 1.14% and a negative net margin of 1.23%. The business had revenue of $28.60 million for the quarter, compared to the consensus estimate of $24.45 million. During the same period in the previous year, the business earned ($1.30) earnings per share. The business’s revenue was up 60.7% on a year-over-year basis. On average, equities analysts predict that Glaukos Corp. will post $0.11 EPS for the current fiscal year.

A number of analysts recently issued reports on the company. Zacks Investment Research cut Glaukos Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, July 5th. Piper Jaffray Cos. reissued an “overweight” rating and set a $40.00 price objective (up previously from $27.00) on shares of Glaukos Corp. in a report on Monday, August 1st. Roth Capital increased their price objective on Glaukos Corp. from $36.50 to $41.00 and gave the stock a “buy” rating in a report on Tuesday, August 2nd. Cantor Fitzgerald reissued a “buy” rating and set a $41.00 price objective on shares of Glaukos Corp. in a report on Sunday, September 25th. Finally, Stifel Nicolaus reissued a “hold” rating on shares of Glaukos Corp. in a report on Tuesday, September 27th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Glaukos Corp. currently has a consensus rating of “Buy” and a consensus price target of $39.20.

In other news, Director Orbimed Advisors Llc sold 425,000 shares of the business’s stock in a transaction dated Wednesday, August 3rd. The stock was sold at an average price of $30.59, for a total value of $13,000,750.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Richard L. Harrison sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $35.01, for a total value of $350,100.00. Following the completion of the transaction, the chief financial officer now owns 11,388 shares in the company, valued at $398,693.88. The disclosure for this sale can be found here. 36.80% of the stock is owned by insiders.

Glaukos Corp. Company Profile

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide.

5 Day Chart for NYSE:GKOS

Receive News & Stock Ratings for Glaukos Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp. and related stocks with our FREE daily email newsletter.